A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Intellectual disability === Dysfunction of Rho proteins has also been implicated in intellectual disability. Intellectual disability in some cases involves malformation of the dendritic spines, which form the post-synaptic connections between neurons. The misshapen dendritic spines can result from modulation of rho protein signaling. After the cloning of various genes implicated in X-linked intellectual disability, three genes that have effects on Rho signaling were identified, including oligophrenin-1 (a GAP protein that stimulates GTPase activity of Rac1, Cdc42, and RhoA), PAK3 (involved with the effects of Rac and Cdc42 on the actin cytoskeleton) and αPIX (a GEF that helps activate Rac1 and Cdc42). Because of the effect of Rho signaling on the actin cytoskeleton, genetic malfunctions of a rho protein could explain the irregular morphology of neuronal dendrites seen in some cases of intellectual disability.
A matricellular protein is a dynamically expressed non-structural protein that is present in the extracellular matrix (ECM). Rather than serving as stable structural elements in the ECM, these proteins are rapidly turned over and have regulatory roles. They characteristically contain binding sites for ECM structural proteins and cell surface receptors, and may sequester and modulate activities of specific growth factors. Examples of matricellular proteins include the CCN family of proteins (also known as CCN intercellular signaling protein), fibulins, osteopontin, periostin, SPARC family members, tenascin(s), and thrombospondins. Many of these proteins have important functions in wound healing and tissue repair.
COVID-19 in the UK: Data from the Office for National Statistics for the week ending 31 January indicates COVID-19 cases have risen in England for the first time in 2023, with 1.02 million cases, an increase of 8% from 941,800 the previous week. Data for Scotland and Wales is less clear. 11 February – Brianna Ghey, a 16-year-old teenage transgender girl is found dead in Warrington Park in Cheshire, England. Two teenagers, a boy and a girl, both 15-years-old are arrested on suspicion of her murder. 13 February – Former Metropolitan Police officer Wayne Couzens pleads guilty to three counts of indecent exposure during a hearing at the Old Bailey, including one committed four days before he killed Sarah Everard in 2021. 14 February – The Welsh government cancels all major road building projects in Wales, including the proposed Third Menai Crossing, amid concerns about the environment. 15 February Inflation falls for the third month in a row, from 10.5% to 10.1%. This is mainly due to a decrease in fuel, restaurant, and hotel prices, according to the ONS. Food inflation remains at 16.7%. Pay, excluding bonuses, rose at an annual pace of 6.7% from October to December 2022, and when inflation is taken into account, regular pay fell by 2.5%. Nicola Sturgeon announces her resignation as First Minister of Scotland and Leader of the Scottish National Party after eight years in the role; she will stay on until her successor has been elected. Two teenagers are charged with murder in relation to the death of Brianna Ghey.
=== Gas chromatography === After extracting rocks or live samples with organic solvents, tetrahymanol, gammacerane, and other lipids can be separated using gas chromatography. This technique separates molecules based on their polarity and size, which both inversely affect boiling point. As a compound's boiling point increases, it spends more time as a condensed liquid in the bonded liquid stationary phase of the GC column. More volatile compounds will partition into the gaseous mobile phase and have a short elution time. Before injection onto the chromatographic column, the alcohol substituent on tetrahymanol is acetylated with acetic anhydride, allowing it to volatilize and enter the GC.
Lithium fluoride had already been proposed in the USA in 1950 by Farrington Daniels (1889-1972), Charles A. Boyd and Donald F. Saunders (1924-2013) for solid-state dosimetry using thermoluminescent dosimeters. The intensity of the thermoluminescent light is proportional to the amount of radiation previously absorbed. This type of dosimetry has been used since 1953 in the treatment of cancer patients and wherever people are occupationally exposed to radiation. The thermoluminescence dosimeter was followed by OSL dosimetry, which is not based on heat but on optically stimulated luminescence and was developed by Zenobia Jacobs and Richard Roberts at the University of Wollongong (Australia). The detector emits the stored energy as light. The light output, measured with photomultipliers, is then a measure of the dose.
Sources: en.wikipedia.org
== ACTH receptors outside the adrenal gland == As indicated above, ACTH is a cleavage product of the pro-hormone, proopiomelanocortin (POMC), which also produces other hormones including α-MSH that stimulates the production of melanin. A family of related receptors mediates the actions of these hormones, the MCR, or melanocortin receptor family. These are mainly not associated with the pituitary-adrenal axis. MC2R is the ACTH receptor. While it has a crucial function in regulating the adrenal glands, it is also expressed elsewhere in the body, specifically in the osteoblast, which is responsible for making new bone, a continual and highly regulated process in the bodies of air-breathing vertebrates. The functional expression of MC2R on the osteoblast was discovered by Isales et alia in 2005. Since that time, it has been demonstrated that the response of bone forming cells to ACTH includes production of VEGF, as it does in the adrenal. This response might be important in maintaining osteoblast survival under some conditions. If this is physiologically important, it probably functions in conditions with short-period or intermittent ACTH signaling, since with continual exposure of osteoblasts to ACTH, the effect was lost in a few hours.
== Mechanism == Biochemical and structural analyses of aminopeptidase (APPro), methionine aminopeptidase (MetAP), and prolidase, all members of the "pita-bread" metalloenzymes, suggest that they share a common mechanism scheme. The main difference arises in the location of the carbonyl oxygen atom of the scissile peptide bond.
Central nervous system: fatigue, dizziness, drowsiness, lightheadedness, confusion, nightmares, agitation, increased anxiety, difficulty sleeping, seizures (infrequently), temporary confusion (delirium), rarely induction of hypomania and psychosis, extrapyramidal side effects (rarely), abuse in patients with polytoxicomania (rarely), ringing in the ears (tinnitus) Anticholinergic: dry mouth, constipation, even ileus (rarely), difficulties in urinating, sweating, precipitation of glaucoma Antiadrenergic: Low blood pressure, (if patient arises too fast from the lying/sitting position to standing—known as orthostatic hypotension), abnormal heart rhythms (e.g., sinus tachycardia, bradycardia, and atrioventricular block) Allergic/toxic: skin rash, photosensitivity, liver damage of the cholestatic type (rarely), hepatitis (extremely rare), leuko- or thrombocytopenia (rarely), agranulocytosis (very rarely), hypoplastic anemia (rarely) Others: frequently increased appetite and weight gain, rarely nausea, rarely high blood pressure. May increase or decrease liver enzyme levels in the blood of some people. The side effects of low-dose doxepin for insomnia in long-term clinical trials (28 to 85 days) in adults and elderly people were as follows:
== History == Results of a Phase I clinical trial were reported in 2016. In December 2019, enfortumab vedotin was approved in the United States for the treatment of adult patients with locally advanced or metastatic urothelial cancer who had previously received a programmed cell death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a platinum-containing chemotherapy. The approval was based on the results of a clinical trial of 125 such patients. The overall response rate, reflecting the percentage of patients who had a certain amount of tumor shrinkage, was 44%; specifically, 12% had a complete response and 32% a partial response. The median duration of response was 7.6 months. The U.S. Food and Drug Administration (FDA) granted the application for enfortumab vedotin accelerated approval, priority review designation, and breakthrough therapy designation. The FDA granted the approval of Padcev to Astellas Pharma US Inc. In July 2021, the FDA approved enfortumab vedotin for adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have previously received therapy.
He maintained that only the vanguard made up of about a thousand men had been destroyed in Tarqui, after having vigorously resisted the entire Gran Colombian army; and he added that his attack on the most immediate plain was awaited in vain after the charge of the Cedeño squadron had been repulsed by the Husares de Junín. He emphasized that the entire Peruvian army had not gathered more than 4,500 men and that by mentioning their number raising it to 8,000, Sucre had made a willful mistake for anti-Peruvian reasons. For all these reasons, he declared the Girón Agreement suspended: "while [...] satisfaction capable of indemnifying the injuries received is given, and the depressive documents are destroyed, the existence of which would drive away even the hope of reconciliation." For this reason, he proceeded to denounce the Girón Agreement, once again preparing to undertake hostilities.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.